申请人:Grelan Pharmaceutical Co., Ltd.
公开号:US06136831A1
公开(公告)日:2000-10-24
The purpose is to provide anti-inflammatory agents which have potent pharmacological actions and exert a selective inhibitory activity on COX-2, thereby being expected to reduce adverse effects such as disorders in gastric mucosa. The present invention encompasses a compound of the formula (1): wherein R.sup.1 is hydrogen or halogen, R.sup.2 and R.sup.3 are each independently hydrogen, halogen, lower alkyl, lower alkoxy, hydroxy or lower alkanoyloxy, R.sup.4 is lower haloalkyl or lower alkyl, X is sulfur, oxygen or NH, and Y is lower alkylthio, lower alkylsulfonyl or sulfamoyl, which exerts superior anti-inflammatory activity, and highly inhibits COX-2 induced in inflamed sites, with less inhibitory action on COX-1 present in stomach, kidney, etc. Pharmaceutical agents comprising the compound of the present invention are provided as selective COX-2 inhibitors, and anti-inflammatory agents rarely accompanying adverse actions including attacks on gastric mucosa.
本发明旨在提供具有强效药理作用并对COX-2具有选择性抑制活性的抗炎药物,从而预期减少胃黏膜紊乱等不良反应。本发明涵盖了以下式(1)的化合物:其中R.sup.1为氢或卤素,R.sup.2和R.sup.3分别独立为氢、卤素、较低烷基、较低烷氧基、羟基或较低烷酰氧基,R.sup.4为较低卤代烷基或较低烷基,X为硫、氧或NH,Y为较低烷基硫基、较低烷基磺酰基或磺酰胺基,具有优越的抗炎活性,并高度抑制炎症部位中诱导的COX-2,在胃、肾等器官中对存在的COX-1的抑制作用较小。包括本发明化合物的药物剂被提供为选择性COX-2抑制剂,并且抗炎药物很少伴随对胃黏膜的攻击等不良作用。